Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs
Abstract Background Decisions relating to the funding of new drugs are becoming increasingly challenging due to a combination of aging populations, rapidly increasing list prices, and greater numbers of drug-indication pairs being brought to market. This is especially true in cancer, where rapid lis...
Main Authors: | Sarah Costa, Colene Bentley, Dean A. Regier, Helen McTaggart-Cowan, Craig Mitton, Michael M. Burgess, Stuart J. Peacock |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12889-019-7303-2 |
Similar Items
-
Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada
by: Colene Bentley, et al.
Published: (2018-05-01) -
The ASTUTE Health study protocol: Deliberative stakeholder engagements to inform implementation approaches to healthcare disinvestment
by: Watt Amber M, et al.
Published: (2012-10-01) -
Disinvestment in India - A Stakeholders' Management Perspective
by: Vilas Kulkarni, et al.
Published: (2016-04-01) -
State ownership and firm performance: A performance evaluation of disinvested public sector enterprises
by: I. Chhabra, et al.
Published: (2021-12-01) -
Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
by: G. E. Calabrò, et al.
Published: (2018-03-01)